TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma

The treatment of renal cell carcinoma (RCC) with chemotherapy remains a challenge; therefore, improving the knowledge of the molecular mechanisms underlying RCC chemoresistance and developing novel therapeutic strategies is important. Dedicator of cytokinesis 1 (DOCK1), the first member of the DOCK...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Med Rep
Main Authors: Zhang, Wei, Zheng, Xiaoxiao, Xie, Shangzhi, Zhang, Shufen, Mao, Jiayan, Cai, Ying, Lu, Xuemei, Chen, Wei, Ni, Haibin, Xie, Liping
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7339706/
https://ncbi.nlm.nih.gov/pubmed/32626999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2020.11243
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados